Survodutide is a dual agonist of the GLP-1 and glucagon receptors, originally developed as a treatment for Type-2 Diabetes and obesity. Like other GLP-1 drugs, it suppresses appetite, increases fat oxidation, and supports metabolic activity. Survodutide has also shown promise as a treatment for non-cirrhotic metabolic-dysfunction-associated steatohepatitis (MASH) and moderate liver fibrosis (F2–F3 stage).
Benefits
- At 46 weeks, participants lost an average of 6 inches from waist circumference
- 19% total body weight loss at 4.8mg weekly
- Significant reduction in blood pressure at 2.4mg or higher
- Potentially beneficial for cardiovascular health
- Ongoing weight loss past 46 weeks suggests longer-term use may yield greater fat reduction
Possible Side Effects
Survodutide shows milder side effects than other GLP-1 drugs in clinical trials. Reported side effects include:
- Injection site irritation (redness, swelling, itching)
- Nausea
- Vomiting
- Diarrhea
Contraindications
- Monitor patients on antihypertensive medications — Survodutide may interact with blood pressure meds
- Do not take if pregnant or breastfeeding
- Do not stop all blood pressure meds without consulting a physician — this may offset Survodutide’s benefits
Stacking Suggestions
- Tirzepatide or Semaglutide (alternate between cycles to prevent GLP-1 receptor desensitization)
- NAD+ or MOTS-C – enhances cellular energy production and mitochondrial repair alongside fat loss
- AOD-9604 – further supports lipolysis during Survodutide’s appetite-suppressing phase
- L-Carnitine Injections – promotes fat transport into mitochondria for oxidation
- Glutathione – reduces oxidative stress and supports liver function (especially in MASH patients)
- CJC-1295/Ipamorelin – enhances lean muscle gain during weight loss phases
For metabolic and liver optimization, Survodutide + Glutathione + NAD+ is a powerful triad. For fat loss, stack with AOD-9604 and CJC-1295/Ipamorelin to preserve lean mass and recover faster.
